Superior efficacy of tumor cell vaccines grown in physiologic oxygen

Clinical Cancer Research

Volumn 16, Issue 19, 2010, Pages 4800-4808

  Olin, Michael R ^a   Andersen, Brian M ^b   Zellmer, David M ^a   Grogan, Patrick T ^c   Popescu, Flavia E ^a   Xiong, Zhengming ^a   Forster, Colleen L ^a   Seiler, Charlie ^a   SantaCruz, Karen S ^a   Chen, Wei ^a   Blazar, Bruce R ^a   Ohlfest, John R ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; GLYCOPROTEIN GP 100; IMMUNOGLOBULIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; OVALBUMIN; OXYGEN; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER LOCALIZATION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL GROWTH; CELL LYSATE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; FEMALE; GLIOMA; GLIOMA CELL; HUMORAL IMMUNITY; HYPOTHESIS; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; OXYGEN TENSION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TISSUE CULTURE; TUMOR IMMUNITY; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CANCER VACCINES; CELL EXTRACTS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLIOMA; IMMUNOHISTOCHEMISTRY; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; OXYGEN; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 77957586485     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1572     Document Type: Article

References (28)

1. Copier J, Ward S, Dalgleish A. Cell based cancer vaccines: regulatory and commercial development. Vaccine 2007;25 Suppl 2:B35-46.
2. Ridgway D. The first 1000 dendritic cell vaccinees. Cancer Invest 2003;21:873-86. (Pubitemid 38055985)
3. Johnson RS, Walker AI, Ward SJ. Cancer vaccines: will we ever learn? Expert Rev Anticancer Ther 2009;9:67-74.
4. Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 2005;11:5515-25.
5. Yamanaka R, Homma J, Yajima N, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 2005;11:4160-7. (Pubitemid 40791581)
6. Tirapu I, Lewis A, Kreutz M, McLinden H, Diebold SS. Freeze-andthaw- disrupted tumour cells impair the responsiveness of DC to TLR stimulation. Eur J Immunol 2008;38:2740-50.
7. Hatfield P, Merrick AE, West E, et al. Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy. J Immunother 2008;31:620-32.
8. Gillies RJ, Gatenby RA. Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis? J Bioenerg Biomembr 2007;39:251-7.
9. Gillies RJ, Gatenby RA. Hypoxia and adaptive landscapes in the evolution of carcinogenesis. Cancer Metastasis Rev 2007;26: 311-7.
10. Poon E, Harris AL, Ashcroft M. Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Rev Mol Med 2009;11:e26.
11. McCord AM, Jamal M, Shankavarum UT, Lang FF, Camphausen K, Tofilon PJ. Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol Cancer Res 2009;7:489-97.
12. Li Z, Bao S, Wu Q, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009;15:501-13.
13. Platet N, Liu SY, Atifi ME, et al. Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. Cancer Lett 2007;258:286-90. (Pubitemid 350110377)
14. Windisch BK, LeVatte TL, Archibald ML, Chauhan BC. Induction of heat shock proteins 27 and 72 in retinal ganglion cells after acute pressure-induced ischaemia. Clin Experiment Ophthalmol 2009;37: 299-307.
15. Tsung A, Klune JR, Zhang X, et al. HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J Exp Med 2007;204:2913-23. (Pubitemid 350179560)
16. Manicassamy S, Pulendran B. Modulation of adaptive immunity with Toll-like receptors. Semin Immunol 2009;21:185-93.
17. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006;5:471-84.
18. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007;117:1184-94.
19. Wu A, Oh S, Ericson K, et al. Transposon-based interferon gamma gene transfer overcomes limitations of episomal plasmid for immunogene therapy of glioblastoma. Cancer Gene Ther 2007;14:550-60. (Pubitemid 46788330)
20. Xiong Z, Gharagozlou S, Vengco I, Chen W, Ohlfest JR. Effective CpG immunotherapy of breast carcinoma prevents but fails to eradicate established brain metastasis. Clin Cancer Res 2008;14:5484-93.
21. Overwijk WW, Theoret MR, Finkelstein SE, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003;198:569-80.
22. Lyons AB. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods 2000; 243:147-54.
23. Olin MR, Hwa Choi K, Lee J, Molitor TW. Gammadelta T-lymphocyte cytotoxic activity against Mycobacterium bovis analyzed by flow cytometry. J Immunol Methods 2005;297:1-11. (Pubitemid 40386384)
24. Wu A, Oh S, Gharagozlou S, et al. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma. J Immunother 2007;30:789-97.
25. Prins RM, Odesa SK, Liau LM. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res 2003;63:8487-91.
26. Porgador A, Yewdell JW, Deng Y, Bennink JR, Germain RN. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 1997;6:715-26. (Pubitemid 27305734)
27. Sitkovsky MV. T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response. Trends Immunol 2009;30: 102-8.
28. Evans SM, Judy KD, Dunphy I, et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 2004;10:8177-84.